<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843348</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ADE44</org_study_id>
    <secondary_id>2011-005238-21</secondary_id>
    <nct_id>NCT01843348</nct_id>
  </id_info>
  <brief_title>12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients</brief_title>
  <acronym>ATHENA</acronym>
  <official_title>12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certican® Based Regimen Either in Combination With Cyclosporin A or Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the renal function comparing Certican based
      immunosuppressive regimens with two different CNIs (Tacrolimus or Cyclosporin A) versus a
      standard treatment with Mycophenolic Acid and Tacrolimus in de novo renal transplant
      recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2012</start_date>
  <completion_date type="Actual">March 23, 2016</completion_date>
  <primary_completion_date type="Actual">March 23, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens</measure>
    <time_frame>One year post transplant</time_frame>
    <description>To demonstrate non-inferiority in renal function assessed by glomerular filtration rate (Nankivell formula) in at least one of the Certican® treatment regimens compared to the standard regimen group at month 12 post-transplantation in renal transplant patients. Nankivell formula:
GFR = 6.7/Scr + BW/4 - Surea/2 - 100/(height)² + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The eGFR is expressed in mL/min per 1.73m². If a patient was on dialysis at the time of urea or creatinine assessment, the eGFR was set to 0. Analysis set = per protocol set</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Composite Treatment Failure Endpoints - Difference Between Groups at Month 12</measure>
    <time_frame>Month 12 post transplant</time_frame>
    <description>Combined endpoint included: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant</measure>
    <time_frame>Month 12 post transplant</time_frame>
    <description>Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method = GFR=141 x min(Scr/κ, 1)α x max(Scr/κ, 1)1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black] where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant</measure>
    <time_frame>Month 12 post transplant</time_frame>
    <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant</measure>
    <time_frame>Month 12 post transplant</time_frame>
    <description>Modification of Diet in Renal Disease (MDRD) = For men: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x (albumin0,318) For women: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x albumin0,318) x 0.762 with urea nitrogen = urea / 2.144. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment Failure Endpoints at Month 12</measure>
    <time_frame>Month 12 post transplant</time_frame>
    <description>Treatment failure endpoints: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Graft Function and Slow Graft Function</measure>
    <time_frame>Post transplant to month 12</time_frame>
    <description>Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day. Slow graft function (SGF) was defined as a serum creatinine &gt;3.0 mg/dL at Day 5 post-transplantation. Full analysis set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Delayed Graft Function by Day</measure>
    <time_frame>Post transplant up to day 7</time_frame>
    <description>Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Viral Infections</measure>
    <time_frame>Post transplant to month 12</time_frame>
    <description>Viral infections for BKV Virus Humane Polyomavirus 1 and Cytomegalovirus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Wound Healing Complications During Study</measure>
    <time_frame>Post transplant until individual reporting</time_frame>
    <description>Information collected to report wound healing process which included percentage of participants with complications, fluid collections detected and occurrence of lymphoceles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Wound Healing</measure>
    <time_frame>Post transplant until individual reporting</time_frame>
    <description>A wound will be considered healed if all the suture material and staples are removed and the wound is intact. Number of participants is based on all patients of the respective treatment group in the safety set, excluding patients with no answer (unknown).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>TAC+MPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAC+Certican</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CycA+Certican</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>TAC+Certican</arm_group_label>
    <arm_group_label>CycA+Certican</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels</description>
    <arm_group_label>TAC+MPA</arm_group_label>
    <arm_group_label>TAC+Certican</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml</description>
    <arm_group_label>CycA+Certican</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric Coated Mycophenolate Sodium (EC-MPS)</intervention_name>
    <description>Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose</description>
    <arm_group_label>TAC+MPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <description>Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose</description>
    <arm_group_label>TAC+MPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>A minimum dose of 5 mg prednisolon or equivalent</description>
    <arm_group_label>TAC+MPA</arm_group_label>
    <arm_group_label>TAC+Certican</arm_group_label>
    <arm_group_label>CycA+Certican</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simulect</intervention_name>
    <description>Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.</description>
    <arm_group_label>TAC+MPA</arm_group_label>
    <arm_group_label>TAC+Certican</arm_group_label>
    <arm_group_label>CycA+Certican</arm_group_label>
    <other_name>Basiliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who had received a primary or secondary kidney transplant

          -  Patients who were willing and from whom written informed consent was obtained

          -  kidney allograft with a cold ischemia time (CIT) &lt; 30 hours

          -  negative pregnancy test prior to study enrollment

        Exclusion Criteria:

        --Multi-organ recipients

          -  former Graft loss due to immunological reasons

          -  Patients who received a kidney from a non-heart beating donor

          -  A-B-0 incompatible transplants

          -  a current Panel Reactive Antibody (PRA) level of &gt; 20%

          -  existing antibodies against the HLA-type of the receiving transplant

          -  a known hypersensitivity/contraindication to any of the immunosuppressants

          -  Use of other investigational drugs

          -  Patients with thrombocytopenia (platelets &lt; 100,000/mm³), with an absolute neutrophil
             count of &lt; 2,000/mm³ or leucopenia (leucocytes &lt; 3,000/mm³), or hemoglobin &lt; 8 g/dL

          -  significant mental illness

          -  history of malignancy during the last five years

          -  HIV positive

          -  uncontrolled hypercholesterolemia or hypertriglyceridemia

          -  drug or alcohol abuse

          -  pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Priest en Jarez Cedex</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 4</city>
        <zip>31054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2013</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>Renal transplant</keyword>
  <keyword>Rejection,allograf</keyword>
  <keyword>Rejection</keyword>
  <keyword>Xenograft rejection</keyword>
  <keyword>Host vs graft disease</keyword>
  <keyword>Kidney Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TAC+MPA</title>
          <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
        </group>
        <group group_id="P2">
          <title>TAC+Certican</title>
          <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
        </group>
        <group group_id="P3">
          <title>CycA+Certican</title>
          <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="208"/>
                <participants group_id="P3" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set (SAS)</title>
              <participants_list>
                <participants group_id="P1" count="204">One participant received TAC + Certican in error - analyzed with TAC + Certican arm</participants>
                <participants group_id="P2" count="210">Two participants received TAC + Certican in other arms in errorr - analyzed with TAC + Certican arm</participants>
                <participants group_id="P3" count="198">One participant received TAC + Certican in error - analyzed with TAC + Certican arm</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="205">Participants in the FAS received at least one dose of study drug</participants>
                <participants group_id="P2" count="208">Participants in the FAS received at least one dose of study drug</participants>
                <participants group_id="P3" count="199">Participants in the FAS received at least one dose of study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Set (PPS)</title>
              <participants_list>
                <participants group_id="P1" count="147">Participants in the FAS without major protocol deviations</participants>
                <participants group_id="P2" count="111">Participants in the FAS without major protocol deviations</participants>
                <participants group_id="P3" count="80">Participants in the FAS without major protocol deviations</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft loss/retransplantation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Various reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set consisted of all randomized patients who received at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>TAC+MPA</title>
          <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
        </group>
        <group group_id="B2">
          <title>TAC+Certican</title>
          <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
        </group>
        <group group_id="B3">
          <title>CycA+Certican</title>
          <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="205"/>
            <count group_id="B2" value="208"/>
            <count group_id="B3" value="199"/>
            <count group_id="B4" value="612"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.3" spread="12.09"/>
                    <measurement group_id="B2" value="54.3" spread="13.50"/>
                    <measurement group_id="B3" value="55.1" spread="12.61"/>
                    <measurement group_id="B4" value="54.9" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens</title>
        <description>To demonstrate non-inferiority in renal function assessed by glomerular filtration rate (Nankivell formula) in at least one of the Certican® treatment regimens compared to the standard regimen group at month 12 post-transplantation in renal transplant patients. Nankivell formula:
GFR = 6.7/Scr + BW/4 – Surea/2 – 100/(height)² + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The eGFR is expressed in mL/min per 1.73m². If a patient was on dialysis at the time of urea or creatinine assessment, the eGFR was set to 0. Analysis set = per protocol set</description>
        <time_frame>One year post transplant</time_frame>
        <population>Protocol analysis set comprised of participants who received at least one dose of study drug without major protocol deviaitons</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens</title>
          <description>To demonstrate non-inferiority in renal function assessed by glomerular filtration rate (Nankivell formula) in at least one of the Certican® treatment regimens compared to the standard regimen group at month 12 post-transplantation in renal transplant patients. Nankivell formula:
GFR = 6.7/Scr + BW/4 – Surea/2 – 100/(height)² + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The eGFR is expressed in mL/min per 1.73m². If a patient was on dialysis at the time of urea or creatinine assessment, the eGFR was set to 0. Analysis set = per protocol set</description>
          <population>Protocol analysis set comprised of participants who received at least one dose of study drug without major protocol deviaitons</population>
          <units>mL/min per 1.73m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 - Day 1 to 60 (146,111,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.62" spread="16.931"/>
                    <measurement group_id="O2" value="60.54" spread="17.310"/>
                    <measurement group_id="O3" value="59.47" spread="16.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 - Day 61 to 136 (143,108,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.36" spread="16.672"/>
                    <measurement group_id="O2" value="61.21" spread="14.771"/>
                    <measurement group_id="O3" value="62.22" spread="16.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 - Day 137 to 228 (142,108,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.05" spread="16.994"/>
                    <measurement group_id="O2" value="62.76" spread="16.763"/>
                    <measurement group_id="O3" value="63.17" spread="16.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 - Day 229 to 319 (140,106,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.47" spread="16.251"/>
                    <measurement group_id="O2" value="64.68" spread="15.507"/>
                    <measurement group_id="O3" value="62.89" spread="14.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month12 - Day 320 to 450 (147,111, 80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.41" spread="16.514"/>
                    <measurement group_id="O2" value="63.34" spread="16.986"/>
                    <measurement group_id="O3" value="61.51" spread="16.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The trial tests the null hypotheses that the treatment difference (investigational minus reference) in mean eGFR at re-assigned visit Month 12 is lower than the non-inferiority margin (Δ) of 7 mL/min per 1.73m2 versus the alternative that the treatment difference is equal to or greater than the non-inferiority margin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) with tx, center, donor type factors. Raw and adjusted means were presented with one-sided p-values for un-shifted and shifted hypothesis, respectively. Significance level = 2.5% (one-sided)</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Least square mean</param_type>
            <param_value>-9.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.82</ci_lower_limit>
            <ci_upper_limit>-4.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The trial tests the null hypotheses that the treatment difference (investigational minus reference) in mean eGFR at re-assigned visit Month 12 is lower than the non-inferiority margin (Δ) of 7 mL/min per 1.73m2 versus the alternative that the treatment difference is equal to or greater than the non-inferiority margin</non_inferiority_desc>
            <p_value>0.0067</p_value>
            <p_value_desc>Analysis of variance (ANOVA) with tx, center, donor type factors. Raw and adjusted means were presented with one-sided p-values for un-shifted and shifted hypothesis, respectively. Significance level = 2.5% (one-sided)</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-5.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.56</ci_lower_limit>
            <ci_upper_limit>-1.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Composite Treatment Failure Endpoints - Difference Between Groups at Month 12</title>
        <description>Combined endpoint included: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)</description>
        <time_frame>Month 12 post transplant</time_frame>
        <population>Full analysis set includes all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O4">
            <title>Tac+Certican - Tac+MPA - Difference Between Groups</title>
          </group>
          <group group_id="O5">
            <title>CycA+Certican -Tac+MPA - Difference Between Groups</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite Treatment Failure Endpoints - Difference Between Groups at Month 12</title>
          <description>Combined endpoint included: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)</description>
          <population>Full analysis set includes all participants who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="413"/>
                <count group_id="O5" value="404"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPAR or graft loss or death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="13.0"/>
                    <measurement group_id="O3" value="24.6"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPAR, graft loss, death, or loss of follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="22.6"/>
                    <measurement group_id="O3" value="32.7"/>
                    <measurement group_id="O4" value="7.0"/>
                    <measurement group_id="O5" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TAC+Certican - TAC+MPA - difference between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Point estimate</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.029</ci_lower_limit>
            <ci_upper_limit>0.093</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>CycA+Certican -Tac+MPA - difference between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Point estimate</param_type>
            <param_value>0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.221</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant</title>
        <description>Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method = GFR=141 x min(Scr/κ, 1)α x max(Scr/κ, 1)1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black] where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
        <time_frame>Month 12 post transplant</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Glomular Filtration Rate (GFR) Via Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Method at Month 12 Post Transplant</title>
          <description>Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method = GFR=141 x min(Scr/κ, 1)α x max(Scr/κ, 1)1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black] where Scr is serum creatinine, κ is 0.7 for females and 0.9 for males, α is 0.329 for females and 0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
          <population>Full analysis set</population>
          <units>mL/min per 1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.62" lower_limit="48.10" upper_limit="55.14"/>
                    <measurement group_id="O2" value="44.42" lower_limit="40.95" upper_limit="47.89"/>
                    <measurement group_id="O3" value="42.44" lower_limit="38.89" upper_limit="45.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant</title>
        <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
        <time_frame>Month 12 post transplant</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Glomular Filtration Rate (GFR) mL/Min Via Cockcroft- Gault Method at Month 12 Post Transplant</title>
          <description>Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
          <population>Full analysis set</population>
          <units>mL/min per 1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.26" lower_limit="55.85" upper_limit="64.68"/>
                    <measurement group_id="O2" value="52.25" lower_limit="47.88" upper_limit="56.61"/>
                    <measurement group_id="O3" value="51.30" lower_limit="46.85" upper_limit="55.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant</title>
        <description>Modification of Diet in Renal Disease (MDRD) = For men: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x (albumin0,318) For women: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x albumin0,318) x 0.762 with urea nitrogen = urea / 2.144. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
        <time_frame>Month 12 post transplant</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Glomular Filtration Rate (GFR) Via Modification of Diet in Renal Disease (MDRD) Method at Month 12 Post Transplant</title>
          <description>Modification of Diet in Renal Disease (MDRD) = For men: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x (albumin0,318) For women: GFR = 170 x (serum creatinine -0,999) x (age-0,176) x (urea nitrogen -0,17) x albumin0,318) x 0.762 with urea nitrogen = urea / 2.144. last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model</description>
          <population>Full analysis set</population>
          <units>mL/min per 1.73m²</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.24" lower_limit="49.62" upper_limit="56.87"/>
                    <measurement group_id="O2" value="45.72" lower_limit="42.11" upper_limit="49.32"/>
                    <measurement group_id="O3" value="43.47" lower_limit="39.75" upper_limit="47.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment Failure Endpoints at Month 12</title>
        <description>Treatment failure endpoints: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)</description>
        <time_frame>Month 12 post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment Failure Endpoints at Month 12</title>
          <description>Treatment failure endpoints: biopsy proven acute rejection (BPAR) defined as a rejection which was acute and proven by biopsy, graft loss (GL) defined as: allograft was presumed to be lost on the day the patient starts dialysis and not able to be removed from dialysis or death. Patients who prematurely discontinued the study: if the patient did not suffer from an event before discontinuation and reason was not related to efficacy, the patient was assessed as having had no event, otherwise the patient was assessed as having had an event. Full analysis set (FAS)</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Biopsy proven acute rejection (BPAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="12.0"/>
                    <measurement group_id="O3" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treated BPAR (tBPAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BPAR - treatment differences at Month 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Pearson’s chi-square test</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>0.028</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.032</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Graft Function and Slow Graft Function</title>
        <description>Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day. Slow graft function (SGF) was defined as a serum creatinine &gt;3.0 mg/dL at Day 5 post-transplantation. Full analysis set</description>
        <time_frame>Post transplant to month 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Graft Function and Slow Graft Function</title>
          <description>Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day. Slow graft function (SGF) was defined as a serum creatinine &gt;3.0 mg/dL at Day 5 post-transplantation. Full analysis set</description>
          <population>Full analysis set</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Delayed graft function (197,187,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slow graft function (195,187,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="48.7"/>
                    <measurement group_id="O3" value="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Delayed Graft Function by Day</title>
        <description>Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day.</description>
        <time_frame>Post transplant up to day 7</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Delayed Graft Function by Day</title>
          <description>Delayed graft function (DGF) was defined as the need for dialysis within the first 7 days post-transplantation, excluding the first post-transplantation day.</description>
          <population>Full analysis set</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>day 1 (8,7,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9"/>
                    <measurement group_id="O2" value="18.4"/>
                    <measurement group_id="O3" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 2 (2,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 3 (5,1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 4 (4,2,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 5 (4,5,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="13.2"/>
                    <measurement group_id="O3" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 6 (1,1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>day 7 (2,4,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="10.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;7 days (9,16,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="42.1"/>
                    <measurement group_id="O3" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Viral Infections</title>
        <description>Viral infections for BKV Virus Humane Polyomavirus 1 and Cytomegalovirus</description>
        <time_frame>Post transplant to month 12</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Viral Infections</title>
          <description>Viral infections for BKV Virus Humane Polyomavirus 1 and Cytomegalovirus</description>
          <population>Safety set</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Viral infections - CMVMissing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - CMVAsymptomatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - CMVMild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - CMVModerate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - CMVSevere</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - BKVAsymptomatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - BKVMild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - BKVModerate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infections - BKVSevere</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Wound Healing Complications During Study</title>
        <description>Information collected to report wound healing process which included percentage of participants with complications, fluid collections detected and occurrence of lymphoceles</description>
        <time_frame>Post transplant until individual reporting</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Wound Healing Complications During Study</title>
          <description>Information collected to report wound healing process which included percentage of participants with complications, fluid collections detected and occurrence of lymphoceles</description>
          <units>Percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="210"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wound healing complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="19.1"/>
                    <measurement group_id="O3" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluids detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7"/>
                    <measurement group_id="O2" value="26.8"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occurrence of lymphoceles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Wound Healing</title>
        <description>A wound will be considered healed if all the suture material and staples are removed and the wound is intact. Number of participants is based on all patients of the respective treatment group in the safety set, excluding patients with no answer (unknown).</description>
        <time_frame>Post transplant until individual reporting</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TAC+MPA</title>
            <description>Tacrolimus, Mycophenolic acid (MPA), corticosteroids and Simulect</description>
          </group>
          <group group_id="O2">
            <title>TAC+Certican</title>
            <description>Tacrolimus, Certican, corticosteroids and Simulect</description>
          </group>
          <group group_id="O3">
            <title>CycA+Certican</title>
            <description>Cyclosporin A, Certican, corticosteroids and Simulect</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Wound Healing</title>
          <description>A wound will be considered healed if all the suture material and staples are removed and the wound is intact. Number of participants is based on all patients of the respective treatment group in the safety set, excluding patients with no answer (unknown).</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="41.13"/>
                    <measurement group_id="O2" value="54.1" spread="61.97"/>
                    <measurement group_id="O3" value="85.3" spread="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Timeframe for AE</time_frame>
      <desc>AE additional description</desc>
      <group_list>
        <group group_id="E1">
          <title>Tac+MPA</title>
          <description>Tac+MPA</description>
        </group>
        <group group_id="E2">
          <title>Tac+Certican</title>
          <description>Tac+Certican</description>
        </group>
        <group group_id="E3">
          <title>CycA+Certican</title>
          <description>CycA+Certican</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="144" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Splenic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Long QT syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall anomaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Parathyroid gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Anal sphincter atony</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Chronic allograft nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Myocarditis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Polyomavirus-associated nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Shunt infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Anastomotic complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Graft haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Perinephric collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Post procedural urine leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Shunt aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Shunt blood flow excessive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Shunt occlusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ureteric anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vascular graft stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level below therapeutic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Blood creatinine decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac monitoring</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus antigen positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell unclassifiable lymphoma high grade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cardiac valve fibroelastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Marrow hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Mucinous adenocarcinoma of appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bladder tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nephrocalcinosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Postrenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal tubular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ureteral necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urinary fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Laryngeal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Renal transplant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Steroid therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vascular anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Phlebitis deep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="196" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Renal transplant</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other disclosure agreement that restricts the right of the PI to discuss or publish trail results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigation from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-779-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

